Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, has released its biosimilar product for autoimmune disease treatment Stelara in Europe, the company's marketing partner said Friday. Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung Bioepis' eighth biosimilar product that has hit the European market, according to Sandoz Group. Samsung Bioepis currently sells four autoimmune disease treatments, including Pyzchiva, two anti-cancer treatments, one eye disease treatment and one blood disease treatment in Europe. Source: Yonhap News Agency
Samsung Bioepis’ new autoimmune disease treatment hits European market
Recent News
Taichung MRT Cars from Fatal 2023 Crash to Be Auctioned Off
November 19, 2026
Study Links Obesity and Fried Foods to Accelerated Biological Aging
November 19, 2026
MOENV Repair Vouchers Claimed Rapidly After Release
November 19, 2026
MOENV’s Repair Voucher Program Sees Rapid Uptake in Taiwan
November 19, 2026
MOENV’s Repair Vouchers Quickly Claimed in Tainan and Taoyuan
November 19, 2026
Taichung MRT Cars from 2023 Crane Accident Set for Auction
November 19, 2026